THE GILL LAB
Our focus on pushing the frontier of CAR therapies has led to several paradigm-shifting innovations including CART123 for acute myeloid leukemia, CAR macrophages for solid tumors, and pairing CART33 treatment with CRISPR-edited CD33-deficient bone marrow transplants. Each of these technologies is currently being pursued in early phase clinical trials, and promises to alter the landscape of cancer immunotherapy and pave the way for further innovation.
Latest News
- First-in-human trial with CAR macrophages shows promise targeting solid tumors Saturday, January 22, 2022
- Rising Penn star Saar Gill gets funding for a next-gen CAR-T startup, adding a new weapon to the mix Tuesday, June 13, 2017